Amgen Stock Price

-2.91 (-1.27%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 2,543,475
Bid Price 223.80
Ask Price 231.11
News -
Day High 230.00


52 Week Range


Day Low 225.17
Company Name Stock Ticker Symbol Market Type
Amgen Inc AMGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-2.91 -1.27% 225.50 20:00:00
Open Price Low Price High Price Close Price Prev Close
228.55 225.17 230.00 225.40 228.41
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
48,560 2,543,475 $ 227.41 $ 578,410,022 - 198.64 - 258.45
Last Trade Time Type Quantity Stock Price Currency
19:32:28 formt 100 $ 225.50 USD


Draw Mode:

Amgen Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 120.63B 534.93M 534.36M $ 25.98B $ 6.43B 10.30 19.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ 7.04 3.40% 08/17/22 -14.54k 0.60%

more financials information »

Amgen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AMGN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week227.99231.87224.56228.022,345,125-2.49-1.09%
1 Month246.48249.23223.30233.062,723,844-20.98-8.51%
3 Months248.28254.16223.30242.092,585,669-22.78-9.18%
6 Months243.57258.45223.30243.262,964,266-18.07-7.42%
1 Year216.00258.45198.64231.822,990,8219.504.4%
3 Years192.80276.69177.05231.532,724,47132.7016.96%
5 Years187.03276.69163.31212.272,856,94238.4720.57%

Amgen Description

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221001 07:20:18